Clinical Trials in Cancer
Jun 01, 2015
Clinical Trials in Cancer
2
CR-UK CLINICAL TRIALS UNITS
Glasgow
Liverpool
Birmingham London• ICR• UCL
WalesSouthampton
Birmingham (paediatrics)
3
HISTORY OF THE CRCTU
Trials unit established in 1976 by George Blackledge Within Queen Elizabeth Hospital
In 1983 secured funding from Cancer Research Campaign (now Cancer Research UK) Moved under the auspices of the University of Birmingham
Accredited by: UK Clinical Research Centre UK National Cancer Research Institute Cancer Research-UK as a Key Centre for Early Drug
Development trials
4
MISSION
To translate cutting edge science into improved patient care, both rapidly and safely, through the design and conduct of large multi-centre/international randomised trials as well as smaller more data intensive phase I trials of novel therapies
Making a difference
5
REMIT Academically –led Cancer Trials
Across all age groups All modalities of treatment Phase I-III trials For Local and National Investigators
KEY STRENGTHS Several decades of expertise
Trial design and trial delivery Core funding from Cancer Research UK
Outstanding /Forefront score at 2012 QQR High success rate in funding applications Major strategic initiatives
6
STRATEGIC INITIATIVES Aug 2009: Liver NIHR BRU Early Phase Trials Team
Integrated programme; translational from biology to bedside
High volume of trials
April 2010: Designated National Trials Unit for Children’s Cancer
National and international leadership
Innovative trial designs for rare diseases
Jan 2011: LLR Trials Acceleration Programme
National leadership
National disease /site network
Dec 2012: Birmingham Surgical Trials Consortium
Collaborative project within BCCT
7
Bladder; 5%
Breast; 11%
Lung; 2%
Sarcoma; 2%
Paed; 22%
Brain; 1%
Gynaecology; 1%Haematology Malignancies; 20%
Head and Neck; 1%
Liver; 4%
Liver-non cancer; 2%
Lung; 2%
Mixed Primary; 4%
Non - Specific; 3%
Ovarian; 1%
Prostate; 3%
Renal; 3%
Skin; 4%Upper GI; 5%
CANCER TRIALS PORTFOLIO
8
CLINICAL IMPACTS
FROM 2007-2012clinical
impacts in wide range of cancersTotal Live and Pre-live funding
> £33.5 Million
9
Bladder; 5%
Breast; 11%
Lung; 2%
Sarcoma; 2%
Paed; 22%
Brain; 1%
Gynaecology; 1%Haematology Malignancies; 20%
Head and Neck; 1%
Liver; 4%
Liver-non cancer; 2%
Lung; 2%
Mixed Primary; 4%
Non - Specific; 3%
Ovarian; 1%
Prostate; 3%
Renal; 3%
Skin; 4%Upper GI; 5%
10
VIGNETTES FROM PAST AND FUTURE
Changing clinical practice in Breast Cancer
Introducing new treatments in Haematology
Influencing paediatric oncology treatment internationally
Developing immune-based therapies
Developing personalised medicine
Developing new strategic areas
11
CHANGING CLINICAL PRACTICE IN BREAST CANCER
12
13
NEAT TRIAL: ANTHRACYCLINES IMPROVE SURVIVAL: Poole et al NEJM 2006 355 (18) 1851-1862
NEATSCIENCE: BENEFIT IN CEP 17 DUPLICATED CASESBartlett et al Lancet Oncol. 2010 Mar;11(3):266-74.`
14
CONFIRMING IN A META-ANALYSISBartlett et al EJC 2010;8(3): 12)
TESTING THE NEW HYPOTHESIS
APPROVED BY CR UK CTAAC and PARTNERSHIP FUNDING WITH PHARMA
15
DUCTAL CARCINOMA IN SITU (DCIS)
16
OVER DIAGNOSIS OF EARLY BREAST CANCER
Over diagnosis is diagnosing healthy women with ‘breast cancer’ who would never otherwise have acquired a breast cancer diagnosis in their lifetime
2000 women screened 3 yearly over 20 years 17.6- 11.4 lives saved 8.6 - 2.3 over diagnosed Duffy J Med Screen 2010
21,683 women diagnosed with breast cancer in 2006 equivalent to 7000 unnecessary breast cancer diagnoses per year in UK Jorgensen JRSM 2010
17
MARMOT REPORT
3 unnecessary breast cancer diagnoses/treatments for one life saved.
18
Adele Frances
19
OBJECTIVES
To evaluate the effectiveness, cost effectiveness and acceptability of no surgical intervention in patients with newly diagnosed, mammogram detected asymptomatic, low risk DCIS.
To define the natural history of low risk DCIS and to predict those patients who require surgery because their DCIS is at risk of progression to invasive disease.
20
LORIS: A multicentre, prospective, Phase III, randomised controlled trial, incorporating an internal feasibility study with stratified 1:1 randomisation
Low or Intermediate Grade DCIS on Vacuum Biopsy
Active monitoring Surgery
Pathology Central review confirms low risk criteria
Randomise
21
OUTCOME MEASURES
Primary outcome measure Ipsilateral invasive breast cancer free survival rate Secondary outcome measures • Overall survival • Mastectomy rate • Time to mastectomy • Time to surgery • Patient reported outcomes (PRO) • Health resource utilisation • Assessment of predictive biomarkers
Potential for major practice
changing outcome
22
INTRODUCING NEW TREATMENTS IN HAEMATOLOGY
23
RELAPSE IS THE MAJOR CAUSE OF TREATMENT FAILURE IN PATIENTS ALLOGRAFTED FOR AML
35-80% allografted for AML relapse: according to disease biology and remission status at time of transplant
Disease relapse occurs early >80% in first year post-transplant
Outcome in patients who relapse after a Reduced intensity conditioning (RIC) allograft for MDS/AML is poor
24
NOVEL STRATEGY TO REDUCE THE RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT IN MDS/AML
Epigenetically manipulate the allo-reactive response post transplant?
Goodyear et al Blood 2010
AZA/VPA pre-treatment on MAGE-specific CTL recognition of a hematopoietic target
25
RIC-AZA PHASE II TRIAL
PROF. CHARLIE CRADDOCK
Day 0
FMC RIC
ALLOGRAFT
Day 30
5-AC36mg/m2 5days
Day 60
Day 120
Day 90
Day 150
Day 365
5-AC 5-AC 5-AC 5-AC5-AC
DLI administration
(if relapse/mixed chimerism)…
26
OBJECTIVES
Primary To assess the tolerability of post-transplant Azacitidine
in patients with AML using a RIC regimen
Secondary To document the impact of post-transplant Azacitidine
on the kinetics of disease relapse
Adjunctive biological studies to study the effect of post-transplant on Azacitidine on immune parameters post-transplant
27
PATIENT COHORT
• 51 patients registered (22 registered pre-transplant, 29 registered post-transplant)
• 37 patients commenced Aza at a median of 55 days post Tx
• 14 patients withdrawn because of:
- post-transplant complications (n=8)
- withdrawal of consent (n=3)
- ineligibility/screening failure (n=3)
• Minimum follow up 12 months
28
CLINICAL RESULTS
• 32 patients completed at least 3 cycles of AZA and 16 patients completed 10
• Of patients who commenced AZA only 4 experienced treatment delay because of hematological toxicity
• 4 patients developed chronic limited GVHD but none chronic extensive GVHD
• 16 of 37 patients relapsed at a median of 8 months• 13 of 33 patients transplanted in remission relapsed
29
AZA INDUCES A TUMOUR SPECIFIC CD8+ T CELL RESPONSE
• 16/28 patients demonstrated CD8+ T cell responses to tumour specific peptides
• Induction of CD*+ T cell response to tumour specific peptides not noted in control population
30
IMPACT OF AZA ON T REG NUMBERSN
o. o
f C
D4
+C
D2
5+
CD
12
7lo
Fo
xP
3+
ce
lls
/L
0
5.0108
1.0109
1.5109
2.0109
p=0.0127
Goodyear et al Blood 2011
31
OVERALL SURVIVAL ACCORDING TO TUMOUR SPECIFIC CD8+ T CELL RESPONSE
p= 0.02
32
CONCLUSIONS
Azacitidine is well tolerated post allograft and is associated with a notably low incidence of chronic GVHD
There is preliminary evidence that the induction of CD8+ specific anti-tumour activity by AZA may prevent disease relapse
The potential for epigenetic manipulation of GVHD and GVL requires further examination in a randomised trial
STRATEGIC REQUIREMENT FOR EFFECTIVE EARLY PHASE CLINICAL TRIAL PROGRAMME
FOR HAEMATOLOGICAL MALIGNACIES
• Large catchment area
• Clinical centres of excellence
• Appropriate trial management infrastructure
• Strong basic science
34
NETWORK - SELECTED CENTRES
TREATMENT ACCELERATION PROGRAMME - OBJECTIVES
• To open 4/5 new trials each year • Open within 6 months
• Recruit in timely fashion
• To complete, analyse and publish results two years after recruitment of first patient
• To strengthen translational studies
36
INFLUENCING PAEDIATRIC ONCOLOGY TREATMENT INTERNATIONALLY
37
NATIONAL CHILDHOOD CANCER AND LEUKAEMIA TRIALS UNIT
CCTT
38
FRAMEWORK TO DELIVER INTERNATIONAL CANCER TRIALS
EU-FP7 funded Network of Excellence for children and adolcescents with cancer (total network funding £12M across 32 partners)
39
39
2/3 of children with metastatic neuroblastoma relapse within 2 yearsAt relapse average survival less than 6
months
NEUROBLASTOMA
40
CURRENT FRONT-LINE CLINICAL TRIAL
41
INTRODUCING NEW THERAPEUTIC APPROACHES
Need to define backbone with relatively low toxicity to add new potential molecularly targeted therapies
Need to test targeted therapies Anti-angiogenics, PI3K/mTOR inhibitors, Aurora
Kinase, IGF-1R, ALK inhibitors…
42
CHALLENGES
Small patient numbers
Non-standard salvage therapy regimes
Multiple potential therapeutic targets
BEACON-Neuroblastoma
ITCC 032
A randomized phase IIb trial of Bevacizumab added to Temozolomide ± Irinotecan for children
with refractory/relapsed neuroblastoma
Andy Pearson, Lucas Moreno, Giuseppe Barone, Keith Wheatley, Veronica Moroz, Elena Brogden, Dee Wherton, Nicola Graham, Sue Burchill, Andrew Peet, Pam Kearns
44
BEACON-NEUROBLASTOMA
Hypotheses
New Agent - The addition of bevacizumab to a backbone chemotherapy regimen (temozolomide or irinotecan-temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma
Backbone - The addition of irinotecan to temozolomide increases the activity of chemotherapy in children with relapsed or refractory neuroblastoma
45
STATISTICAL CONSIDERATIONS
Factorial design Primary Endpoint: ORR after two courses Randomisation stratified
relapsed / refractory disease measurable / evaluable disease early / late relapse (18 months)
BEV randomisation (15% better ORR), (2 stage Minimax Jung)
IRN randomisation: Bayesian methodology
46
DESIGN
Phase II, randomized, open label, 4-arm factorial trial
Relapsed/ Refractory
Neuroblastoma fulfils eligibility
criteria
BACKBONE RANDOMISATION
Temozolomide
Temozolomide + Bevacizumab
Temozolomide + Irinotecan
Temozolomide + Irinotecan + Bevacizumab
BEVACIZUMAB RANDOMISATION
47
INTERNATIONAL COLLABORATION
International Sponsor University of Birmingham CRCTU
CI Andy Pearson
8 National Coordinating CentresNational coordinating investigator
identified in each country
• Regulatory submissions• Initiation of sites• Monitoring• Funding
20-26 SitesPrincipal investigator in each site
Ruth Ladenstein - AustriaHervé Rubie – FranceAurora Castellano – ItalyVictoria Castel - SpainJochen Rößler - GermanyHuib Caron – NetherlandsKarsten Nysom - Denmark
48
BEACON COLLABORATING PARTNERS
CRCTU-BEACON teamo Elena Brogdeno Dee Whertono Keith Wheatleyo Veronica Morozo Pam Kearns
The Institute of Cancer Research – The Royal Marsden Hospitalo Chris Joneso David Collinso Martin Leacho Mu Koho Keiko Miyazakio Regan Barfoot
• Functional Imagingo Andrew Peeto CRUK FI Programme
• Leeds Institute of Molecular Medicineo Sue Burchill
• SIOPENo Peppy Brocko Executive Board
• ITCCo Birgit Geoergero Clinical Trials Committee
• Funderso Cancer Research UKo Imagine for Margoo Roche – Genentech
o Raphael Rousseauo Celine Pallaud
• Patients and families
49
PAEDIATRIC TRIAL PORTFOLIO
no CCTT trial
ALL
Hodgkin lymphoma
b-NHL
Hepato-blastoma
medullo/PNET
LGG
HR Neurob-lastoma
Ewings
RMS
CNS GCTProportion of patients at first diagnosis eligible for a trial 2012/13 ~67%
TRIALS OPEN BY END OF 2013
50
DEVELOPING IMMUNE-BASED THERAPIES
Dan Palmer, Syed Hussain, Neil Steven, Simon Olliff, Stuart Curbishley, Dave Adams
USING DENDRITIC CELLS TO STIMULATE IMMUNE RESPONSES
52
Hepatocellular carcinoma 5th commonest cause of cancer death Promoted by defective immune responses Poor prognosis and few effective treatments Evidence of activity of immunotherapy
STIMULATING IMMUNE RESPONSES TO TREAT HEPATOCELLULAR CARCINOMA
Response to cytokine therapy & adoptive immunotherapyTakayama T et al Lancet 2000
HCC is infiltrated by T cells which after in vitro expansion kill autologous tumour Yoong et al J Immunol 1998; Hepatology 1999; Br J Cancer 1999
53
DEVELOPING A CELLULAR CANCER VACCINE
2008 Palmer: Hepatology – single arm trial of immature lysate loaded DC
2011 Steele: Gene Therapy – single arm trial of cytokine-matured antigen transfected DC
2010 - phase 0 study tracking matured DC in vivo 2014 – ImmunoTACE trial matured lysate DCV
Patients with HCC TACE
Low dose cyclophos-phamide
DCV
No DCV
20% absolute improvement in 1-year PFS rates
54
Pre-treatment 3 cycles 5 cycles8 x 3cm 3 x 2cm 3 x 2cm
Palmer et al Hepatology 2009
2008 CLINICAL RESPONSE AND FALL IN AFP AFTER DC VACCINATION WITH AUTOLOGOUS DCS PULSED WITH HEPG2
LYSATES
Caudate lobe lesion
55
PHASE II STUDY OF ADOPTIVE IMMUNOTHERAPY USING DENDRITIC CELLS PULSED WITH TUMOUR LYSATE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Palmer et al Hepatology 2009
SAFE
• 134 infusions in 34 patients
• no serious toxicity
EVIDENCE OF EFFICACY
• 25 patients received >3 vaccine infusions
• disease control rate 28%
56
IMMUNOTACE CI DAVE ADAMS
PHASE II STUDY OF DC THERAPY IN HCC PLUS ABLATIVE THERAPY WITH TACE
• Low-dose cyclophosphamide to deplete Regulatory T cells
• TACE..transcatheter-arterial embolisation
• Tumour-pulsed DC injected into tumour site
• Monthly iv DC injections
• Outcomes
• Immune monitoring
• Clinical and radiological response
• Delivery monitored by imaging
DEVELOPING PERSONALISED MEDICINE
58
CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME (SMP): PHASE 2
“NATIONAL SCREENING TO NATIONAL TRIALS”
SMP Phase 1 (July 2011 - July 2013) Pilot study of national routine molecular screening of patients
with cancer demonstrating feasibility
3 Technology Hubs (Birmingham, Cardiff, Royal Marsden) and 25 hospitals
9000 patients and 40,000 molecular tests
59
CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME (SMP): PHASE 2
“NATIONAL SCREENING TO NATIONAL TRIALS”
Focus on lung cancer, primarily late-stage metastatic disease: 2,000 patients per year
Large volume national molecular pre-screening Biopsy and cytology samples rather than resection Multiplexed technology solution
‘National Matrix Study’: national trial testing multiple experimental drugs with treatment allocation according to molecular phenotype
60
NATIONAL MATRIX TRIAL
Competitive bid for Chief Investigator, Statistician, Trials Unit – October 2013
• Chief Investigator: Professor Gary Middleton
• Trial Statistician: Professor Lucinda Billingham
• CRCTU: Steven (PI), Kearns, Middleton, Billingham, Morton, Griffiths, Taniere
61
NATIONAL MATRIX STUDY
Drug 1 Drug 2 Drug 3 Drug 4 etc
Biomarker 1
Biomarker 2
Biomarker 3
Biomarker 4
Biomarker 5
Biomarker 6
Biomarker 7
Biomarker 8
etc
Series of single arm phase II trials within a single protocol
62
FULL DETAILS STILL UNDER-WRAPS
WE CAN REVEAL MORE NEXT YEAR
63
DEVELOPING NEW STRATEGIC AREAS
64
PHASE III RANDOMISED CONTROLLED TRIAL COMPARING ALTERNATIVE REGIMENS FOR ESCALATING TREATMENT OF INTERMEDIATE AND HIGH-RISK OROPHARYNGEAL CANCER
COMPARE
CI: PROF HISHAM MEHANNAINSTITUTE OF HEAD AND NECK STUDIES AND EDUCATION,
SCHOOL OF CANCER SCIENCES, UNIVERSITY OF BIRMINGHAM
65
COMPARE DESIGN
Multi-arm, multi-modal (MAMS) design
Efficient design, allows earlier assessment and substitution of arms
Several arms: assess at successive stages Discard arms that show no promise
66
Arm 1 (Control)Concomitant
Cisplatin + RT
Arm 3:Induction TPF +
Arm 1
Arm 4: Cisplatin + Dose-escalated
RT
Arm 2:Surgery+Arm1
Interim stages
(1yr DFS)
Efficacy stage
Primary OutcomeOverall survival
Secondary OutcomesDisease free survival, Acute and late severe toxicity using CTCAE, QoL using EORTC QLQ-C30 & HN35, EQ-5D &
MDADI (for Swallowing), Cost-effectiveness, Surgical complications Others: Molecular markers
PopulationIntermediate or high risk OPC, 16-70yrs, ECOG PS 0-1, Fit for surgery and chemotherapy.
RANDOMISE 630 patientsStratify Intermediate vs High risk & Centre.
Adjust for Site (Tonsil vs Base of Tongue) and size (T1-3 vs T4) of tumour and nodes (N0-2A vs N2B-3)
CompARE
67
CHANGING CLINICAL PRACTICE WITH CRCTU
CTUs are resource-rich research groups
Systematic reviews, meta-analyses
Clinical trials methodology
Support translation of pre-clinical data Drug development trials Integration of biomarkers into trial design Development of novel end-points for targeted
therapies
Tissue with clinical data sets
68
SUMMARY OF CRCTU’S STRATEGIC AIMS FOR 2012-2017
Develop the strengths in our portfolio including:
Translational opportunities in late phase trials
Integration of Stratified Medicine Programme
Early drug development trials: Haematology and Cell therapy/immunotherapy
Innovative and International trials for rare tumours
ACKNOWLEDGMENTS
CRCTU Directors Keith Wheatley Cindy Billingham Dan Rea Neil Steven Charlie Craddock Sarah Bowden
All CRCTU investigators incl; Hisham Mehanna Gary Middleton Adele Francis
Funders CRUK LLR EU FP7 NIHR Imagine for Margot Brain Tumour Trust Industrial Partners
THE CRCTU TEAM